Phase II Trial of Daratumumab for Transplant-Eligible Multiple Myeloma Patients
Phase of Trial: Phase II
Latest Information Update: 06 May 2019
Price : $35 *
At a glance
- Drugs Daratumumab (Primary) ; Autologous stem cell therapy; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 May 2019 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 01 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
- 09 Apr 2018 Status changed from not yet recruiting to recruiting.